Dr. Andes is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
600 Highland Ave
Madison, WI 53792Phone+1 608-263-0943Fax+1 608-263-9103
Education & Training
University of Wisconsin Hospitals and ClinicsFellowship, Infectious Disease, 1996 - 1999- University of Wisconsin Hospitals and ClinicsResidency, Internal Medicine, 1992 - 1996
University of Missouri-Columbia School of MedicineClass of 1992
Certifications & Licensure
WI State Medical License 1993 - 2025- American Board of Internal Medicine Infectious Disease
Awards, Honors, & Recognition
- Association of American Physicians Association of American Physicians, 2018
- American Academy of Microbiology - Fellow American Academy of Microbiology, 2017
- Regional Top Doctor Castle Connolly, 2014
- Join now to see all
Publications & Presentations
PubMed
- Piperacillin/Tazobactam Susceptibility Test Interpretive Criteria for Enterobacterales: Recommendations From the United States Committee on Antimicrobial Susceptibilit...Thomas P Lodise, Sujata M Bhavnani, Paul G Ambrose, Helio S Sader, David Andes
Clinical Infectious Diseases. 2024-12-17 - pharmacodynamic evaluation of the novel nystatin derivative BSG005 in the invasive candidiasis and invasive pulmonary aspergillosis mouse models.Alexander J Lepak, Justin Massey, Robert Zarnowski, Tine K Olesen, Ryley Jones
Antimicrobial Agents and Chemotherapy. 2024-12-05 - The distinctive pharmacokinetic profile of rezafungin, a long-acting echinocandin developed in the era of modern pharmacometrics.David Andes, Roger J Brüggemann, Shawn Flanagan, Alexander J Lepak, Russell E Lewis
The Journal of Antimicrobial Chemotherapy. 2024-11-14
Press Mentions
The Fight Against FungiFebruary 28th, 2021- UWCCC Small Molecule Screening Facility Validates the Lumit™ Dx SARS-CoV-2 Immunoassay for High-Throughput SARS-CoV-2 Antibody ScreeningJanuary 4th, 2021
- Hospitals Stretched Beyond 'Reasonable Limit' as Number of COVID-19 Patients Reaches 100,000December 3rd, 2020
- Join now to see all
Grant Support
- Antifungal Resistance Mechanism In Biofilm Growing Candida AlbicansNational Institute Of Allergy And Infectious Diseases2008–2011
- Training In The Use Of Bruker And Varian Spectrometers And NMRNational Center For Research Resources2010
- Fluconazole-Biofilm Matrix In Candida AlbicansNational Center For Research Resources2010
- Pharmacodynamics In Antifungal ResistanceNational Institute Of Allergy And Infectious Diseases2001–2005
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
